ArticlePLoS medicine2017
An open source pharma roadmap.
Article in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.Chemical Society reviews · 2026Review
- Combating Antimicrobial Resistance: Role of Key Stakeholders with Focus on the Pharmaceutical Sector.Pharmaceutical medicine · 2025Review
- Target 2035 - an update on private sector contributions.RSC medicinal chemistry · 2023Article
- Low-cost anti-mycobacterial drug discovery using engineered E. coli.Nature communications · 2022Article
- Article
- There is no market for new antibiotics: this allows an open approach to research and development.Wellcome open research · 2021Article
- Madurella mycetomatis causing eumycetoma medical treatment: The challenges and prospects.PLoS neglected tropical diseases · 2020Review
- Anthelmintic drug discovery: target identification, screening methods and the role of open science.Beilstein journal of organic chemistry · 2020Review
- Six Laws of Open Source Drug Discovery.ChemMedChem · 2019Article
- An analysis and metric of reusable data licensing practices for biomedical resources.PloS one · 2019Article
- Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?Journal of translational medicine · 2018Review
- Ideation and implementation of an open science drug discovery business model - M4K Pharma.Wellcome open research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In an Essay, Matthew Todd and colleagues discuss an open source approach to drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.